Contact: Hector Munoz
Location: Tarrytown, NY 10591
Email: hmunoz@technovax.com
Tel: +1-914-345-2300 ext. 12
Website: www.TechnoVax.com

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health — Larta Institute

National Institutes of Health Commercialization Assistance Program (NIH-CAP)

Company Profile

Industry Sector: Biotech Vaccine Discovery and Development

Company Overview: We use our proprietary virus-like particle (VLP) technology platform to discover highly active, yet safe, vaccines and then perform initial development. **Successful pre-clinical milestones** have been achieved with several pandemic influenza candidates (H5N1, H7N7, H1N1-1918) and we aim to initiate human clinical trials by year-end 2010.

The technology was invented by Dr. Galarza while a Principal Scientist at **Wyeth**. The company was founded in 2004 by Dr. J. Galarza based on a license from Wyeth with co-exclusivity on certain indications. TechnoVax benefits from over **$5 million** invested in the VLP technology platform since 1996.

Target Market(s):
Annual vaccine sales worldwide are projected to reach ***$18 billon*** and to increase ***12%*** per year.

- Large and medium sized players, within the **Pharmaceutical Industry**, active or looking to enter the infectious diseases market.
- **Regional and local markets** with no current vaccine production capabilities seeking to take control of their national demand and supply.

Key Value Drivers

Technology: TechnoVax has developed a novel way to produce highly immunogenic, **non-infectious** monovalent and **polyvalent virus-like particle vaccines** using a **cell-based manufacturing system** requiring **no chemical inactivation**. The technology is used to produce mass market vaccines for infectious diseases including **influenza**, respiratory syncytial virus (**RSV**), para-influenza virus (**PIV**) and other diseases such as **Dengue, HIV and cancer**.

Competitive Advantage: TechnoVax's novel polyvalent VLP vaccines are produced in a **high yield single manufacturing step** utilizing a new, low investment, manufacturing process, **reducing manufacturing time, steps and costs**.

Plan & Strategy: Actively seeking **strategic partners** in our **target markets**:

- At regional level;
- Product centered;
- Project oriented;

We plan to develop and commercialize ***safe and efficacious novel vaccines*** with the most time and cost-effective manufacturing technology in order to unlock ***significant commercial and competitive advantages.***

**Technology funded by the NIH grants and being commercialized under the NIH-CAP*

Management

Leadership:

Jose M. Galarza, President and CEO. 27 years of academic and industrial experience in the fields of virology and vaccine development.
George Martin, Chief Technical Officer. Scientist Emeritus at the National Institutes of Health and former Senior Vice President for Scientific Affairs of Fibrogen, Inc.
Hector Munoz, VP Business Development and CFO. 20 years of US and international experience in senior management positions in Business Development, Corporate M&A and Trade Marketing.

Scientific Advisory Board:

Doris Bucher, PhD, Professor Dept. of Microbiology and Immunology, New York Medical College.
Nathan Litman, MD, Professor of Pediatrics, Albert Einstein College of Medicine, and Director of Pediatrics and Pediatric Infectious Diseases, Children's Hospital at Montefiore.
Raphael P. Viscidi, MD, Professor of Pediatrics at Johns Hopkins University School of Medicine.
Stephen Udem, MD, PhD, internationally recognized virologist and vaccinologist and former Vice President of Wyeth vaccine division.

Product Pipeline and IP

	Discovery	Pre-clinical	Phase I	Phase II	Phase III
TVX001 – Seasonal Influenza	✓✓✓✓	✓✓✓✓	Q4-2010	Q3-2011	Q2-2012
TVX002 H1N1/ SW flu A	✓✓✓✓	✓✓✓✓	Q4-2010	Q3-2011	Q2-2012
TVX003 - H5N1	✓✓✓✓	✓✓✓✓	TBD		
TVX004 H1N1 (1918)	✓✓✓✓	✓✓✓✓	TBD		
TVX005 - H7N7	✓✓✓✓	✓✓✓✓	TBD		
TVX006 Undisclosed Target	✓✓✓✓	2010			
TVX007-11 Undisclosed Targets	✓✓✓✓	TBD			

- Patented technology and licensed by Wyeth with the option to sub-licence.
- Co-exclusive license with Wyeth for other respiratory virus targets (RSV, PIV, etc.)
- Additional patent applications protect proprietary VLP production for RSV, HIV as well as manufacturing methods.